Literature DB >> 15944947

New aspects on the role of lipoxygenases in cancer progression.

A Catalano1, A Procopio.   

Abstract

The Lipoxygenases (LOXs) are a class of enzymes that convert arachidonic, linoleic, and other polyunsaturated fatty acid into biologically active metabolites involved in the inflammatory and immune responses. Recent evidences indicate that LOXs and the signaling pathways that are involved in their activation are also important for carcinogenesis and tumor progression. LOXs should therefore receive as much attention from cancer researchers as it has already from immunologists. In this article, we will review some evidence that the LOXs pathways affect several aspects of lung, pancreatic and prostate cancer progression. Moreover, we discuss how this new perspective on the roles of LOXs and their metabolites can have important implications to cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944947     DOI: 10.14670/HH-20.969

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  14 in total

1.  Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase.

Authors:  Diane K Luci; J Brian Jameson; Adam Yasgar; Giovanni Diaz; Netra Joshi; Auric Kantz; Kate Markham; Steve Perry; Norine Kuhn; Jennifer Yeung; Edward H Kerns; Lena Schultz; Michael Holinstat; Jerry L Nadler; David A Taylor-Fishwick; Ajit Jadhav; Anton Simeonov; Theodore R Holman; David J Maloney
Journal:  J Med Chem       Date:  2014-01-06       Impact factor: 7.446

2.  Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase.

Authors:  Victor Kenyon; Ganesha Rai; Ajit Jadhav; Lena Schultz; Michelle Armstrong; J Brian Jameson; Steven Perry; Netra Joshi; James M Bougie; William Leister; David A Taylor-Fishwick; Jerry L Nadler; Michael Holinstat; Anton Simeonov; David J Maloney; Theodore R Holman
Journal:  J Med Chem       Date:  2011-07-08       Impact factor: 7.446

3.  Non-small-cell lung cancer pathological subtype-related gene selection and bioinformatics analysis based on gene expression profiles.

Authors:  Jiangpeng Chen; Xiaoqi Dong; Xun Lei; Yinyin Xia; Qing Zeng; Ping Que; Xiaoyan Wen; Shan Hu; Bin Peng
Journal:  Mol Clin Oncol       Date:  2017-11-27

4.  A novel positive feedback loop involving FASN/p-ERK1/2/5-LOX/LTB4/FASN sustains high growth of breast cancer cells.

Authors:  Nan Hu; Yu Li; Yu Zhao; Qi Wang; Jia-cong You; Xiao-dong Zhang; Li-hong Ye
Journal:  Acta Pharmacol Sin       Date:  2011-06-06       Impact factor: 6.150

5.  The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.

Authors:  Seok-Woo Park; Dae-Seog Heo; Myung-Whun Sung
Journal:  Cell Oncol (Dordr)       Date:  2011-06-08       Impact factor: 6.730

6.  Improved innate immune responses by Frondanol A5, a sea cucumber extract, prevent intestinal tumorigenesis.

Authors:  Naveena B Janakiram; Altaf Mohammed; Taylor Bryant; Stan Lightfoot; Peter D Collin; Vernon E Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2015-02-05

7.  Non-synonymous polymorphism (Gln261Arg) of 12-lipoxygenase in colorectal and thyroid cancers.

Authors:  Vidudala V T S Prasad; Kolli Padma
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

Review 8.  Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.

Authors:  Bei Wang; Lujin Wu; Jing Chen; Lingli Dong; Chen Chen; Zheng Wen; Jiong Hu; Ingrid Fleming; Dao Wen Wang
Journal:  Signal Transduct Target Ther       Date:  2021-02-26

Review 9.  Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors.

Authors:  Polamarasetty Aparoy; Kakularam Kumar Reddy; Pallu Reddanna
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

10.  Antinociceptive and antitumor activity of novel synthetic mononuclear Ruthenium (II) compounds.

Authors:  Shyam Sunder A; Satyavati Dhulipala; Sreekanth Thota; Rajeshwar Yerra; Jan Balzarini; Erik De Clercq
Journal:  J Res Med Sci       Date:  2013-03       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.